Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Combined with Iparomlimab/Tuvonralimab and Bevacizumab for Unresectable HCC
NCT07128251Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Aug 2025
- Primary completion
- Jan 2028
- Sponsor
- The First Affiliated Hospital of USTC
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Progression-Free Survival at 2 years. Planned start Aug 2025; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Experimental Group
TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection.
03
Who it enrols
Adult patients with unresectable, non-metastatic HCC, Child-Pugh A, ECOG 0-1, and no prior systemic or locoregional therapy.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Objective Response Rate
Disease Control Rate
Overall Survival
Adverse Events
Beyond the preview
Go deeper on NCT07128251.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128251.